Analysis of the efficacy and influencing factors of double-dose furmonertinib for advanced EGFR ex20ins non-small cell lung cancer
Double-dose furmonertinib demonstrates significant efficacy and favorable tolerability in advanced EGFR ex20ins-mutant NSCLC, particularly in treatment-naïve patients. Pretreatment peripheral T-lymphocyte profiles and systemic inflammatory indices may serve as predictive biomarkers for therapeutic response and prognosis.
Authors
- Yi Ge (ORCID: https://orcid.org/0009-0005-9193-7134)
- Kexin Zhang (ORCID: https://orcid.org/0000-0001-8950-2178)
- Chuhan Zhang (ORCID: https://orcid.org/0009-0003-1505-6787)
- Yihua Xu (ORCID: https://orcid.org/0009-0008-7116-755X)
- Liping Wang (ORCID: https://orcid.org/0000-0002-3750-8946)
Institutions
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1186/s12967-025-07114-w
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00